Paper Details

  1. Home
  2. Paper Details

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.

Author: DurantJacques, GirardPierre-Marie, González-GarcíaJuan, GrinsztejnBeatriz, HorbanAndrzej, JanssenKatrien, LathouwersErkki, MontesMaria Luisa, NelsonMark, Ortega-GonzalezEnrique, Ouwerkerk-MahadevanSivi, RiveroAntonio, SasadeuszJoe, WitekJames, ZakharovaNatalia

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A Phase IIIb, multicenter study of 162 patients with hepatitis C virus genotype 1 (HCV-1)/HIV-1 co-infection found that telaprevir-based therapy plus pegylated-IFN α2a and ribavirin resulted in significantly higher sustained virological response (SVR) rates compared with pre-specified historical controls. The safety profile was comparable to that in HCV-monoinfected patients.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients. PATIENTS AND METHODS: Open-label, Phase IIIb, multicentre study ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkv323

データ提供：米国国立医学図書館（NLM）

Telaprevir-Based Therapy in Patients Coinfected with HCV and HIV: The INSIGHT Study

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection is a complex health challenge, akin to navigating a vast and treacherous desert. This study, INSIGHT, investigates the efficacy, safety, and pharmacokinetics of telaprevir-based therapy in patients coinfected with HCV genotype 1 and HIV-1. The researchers evaluated telaprevir's effectiveness in combination with pegylated interferon (Peg-IFN) α2a and ribavirin, while patients were on stable HIV antiretroviral therapy (HAART).

Navigating the Desert of Coinfection: Telaprevir-Based Therapy

The study revealed that telaprevir-based therapy achieved significantly higher sustained virological response (SVR) rates in both treatment-naive and treatment-experienced HCV/HIV coinfected patients compared to historical controls. This suggests that telaprevir could be a valuable tool for managing HCV infection in patients with coinfection.

Finding a Path Through the Sandstorms: Safety and Tolerability of Telaprevir

The study also found that the safety profile of telaprevir-based therapy in HCV/HIV coinfected patients was comparable to that observed in HCV-monoinfected patients. This finding is encouraging, suggesting that telaprevir may be a safe and effective treatment option for coinfected individuals.

Dr. Camel's Conclusion

The INSIGHT study provides valuable information on the efficacy and safety of telaprevir-based therapy for patients coinfected with HCV and HIV. This research offers a beacon of hope in the challenging landscape of coinfection, paving the way for improved management of HCV in this patient population.

Date :
  1. Date Completed 2016-10-05
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26483516

DOI: Digital Object Identifier

10.1093/jac/dkv323

Related Literature

Article Analysis
・Side Effects of etravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.